Mitozantrone and High-Dose Cytarabine in Adult Acute Myeloid Leukaemia

Marcus, Robert; Catovsky, Daniel; Goldman, John M.; Galton, D. J.; Newland, A. C.; Slocombe, G. W.; Hegde, U. M.

doi:10.1016/s0140-6736(85)91799-4

Cited by 16 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study of HD-ara-C/mitox is based on the multi center trial by the German AML Cooperative Group and is thus applied under standardized conditions for prior therapy as well as for the eligibility for phase I/II-trials [4,5,13,14], The response rate of 50% CR demonstrates a high antileuke mic efficacy of HD-ara-C/mitox even in AML considered to be refractory against conventional therapy. These data compare favorably with other HD-ara-C combinations and confirm that anthracyclines substantially add to the antileukemic activity of HD-ara-C in cases resistant against conventional dose ara-C [1,12,15,25,29], A different regimen of HD-ara-C/mitox has recently been shown to produce similar remission rates although 4 of 10 patients needed more than 1 treatment course to achieve a CR [18]. Even at the highest dose level of mitox lOmg/nr/d x 5 the regimen was well tolerated.…”

Section: Discussionsupporting

confidence: 54%

High-Dose Cytosine-Arabinoside and Mitoxantrone in Refractory Acute Myeloid Leukemia: A Clinical Phase I/II-Study

Hiddemann¹,

Kreutzmann²,

Straif³

et al. 1986

Oncol Res Treat

View full text Add to dashboard Cite

In a multi-institutional study 26 patients with refractory acute myeloid leukemia were entered into a phase I/II study of HD-ara-C and mitox. HD-ara-C 3g/m² q 12 h was given by 3h infusion on days 1-4. Mitox was started at 12mg/m²/d on days 3, 4 and 5, and escalated to 4 and 5 doses of 10mg/m²/d on days 2-5 and 2-6, respectively. From 24 patients presently evaluable for response, 12 achieved a CR and 2 a PR. 7 patients died of infectious complications within the first 4 weeks of treatment while persistent AML was found in 3 cases. Except for one death, possibly related to acute cardiomyopathy, toxicity was mild to moderate consisting of nausea and vomiting, mucositis and diarrhea. These data indicate a high anti-leukemic activity of HD-ara-C/mitox in AML refractory against conventional chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 54%

High-Dose Cytosine-Arabinoside and Mitoxantrone in Refractory Acute Myeloid Leukemia: A Clinical Phase I/II-Study

Hiddemann¹,

Kreutzmann²,

Straif³

et al. 1986

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…The reported remission rates range from 36 to 62% with combinations of high-dose Ara-C and mitoxantrone [12][13][14], and 38 to 66% with high-dose Ara-C and L-asparaginase [19,20]. As for ALL, complete remis sion rates for such patients have been reported to be in the range of 36% to 50% using a high-dose Ara-C and mitox antrone [11,21,22] and 50% with standard dose Ara-C plus mitoxantrone [15].…”

Section: Discussionmentioning

confidence: 99%

Mitoxantrone and Standard Dose Cytosine Arabinoside Therapy in Refractory or Relapsed Acute Leukemia

Keskïn

Tombuloğlu²,

Büyükkeçeci³

1994

Acta Haematol

View full text Add to dashboard Cite

Thirty adult patients with relapsing or refractory acute leukemia were treated with mitoxantrone 10 mg/m2 daily by 20-min intravenous infusion for 5 days and cytosine arabinoside (Ara-C) 200 mg/m² daily by continuous infusion for 5 days. Complete remission was obtained in 9 of 15 patients (60%) with acute myeloblastic leukemia (AML), with a mean duration of 6 months (range 2-12 months). Among 15 patients with acute lymphoblastic leukemia (ALL), complete remission was obtained in 5 patients (33.3%), with a mean duration of 2 months. Partial remission was achieved in 2 patients with AML and 1 patient with ALL. Myelosuppression developed in all patients following chemotherapy. Nonhematologic side effects consisted of nausea, vomiting, mild alopecia, stomatitis and transient hepatic dysfunction. No cardiopulmonary toxicity or neurotoxicity was observed. Our therapeutic responses are similar to those obtained with high-dose Ara-C and mitoxantrone but with less toxicity.

show abstract

“…To combine cytarabine with mitoxantrone in stead of anthracyclines like daunorubicin or doxoru bicin may reduce the cardiac toxicity [6,7], still main taining the same antileukemic effect [2,8,9], The addition of etoposide to standard daunorubicin-cytarabine treatment was recently reported to significant ly increase remission duration and survival in ANLL patients up to 55 years of age [10,11].…”

Section: Discussionmentioning

confidence: 99%

Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia

et al. 1990

View full text Add to dashboard Cite

In a phase I/II study mitoxantrone and etoposide, in combination with cytarabine, were given to 26 patients with refractory, relapsed, and previously untreated acute nonlymphocytic leukemia. Therapy consisted of mitoxantrone 12 mg/m²/day for 3 days, etoposide 100 mg/m²/day and cytarabine 1 g/m² twice a day for 5 days. A total of 14 complete remissions (CR, 54%) were noted. Among refractory patients 5 of 10 achieved a CR as compared to 5 of 6 in the previously untreated group. A favorable response was also seen in patients with late relapse off treatment (3/4 CR) while patients relapsing on therapy did worse (1/6 CR). The results suggest a high antileukemic activity and a moderate toxicity for this drug combination.

show abstract

Mitozantrone and High-Dose Cytarabine in Adult Acute Myeloid Leukaemia

Cited by 16 publications

References 0 publications

High-Dose Cytosine-Arabinoside and Mitoxantrone in Refractory Acute Myeloid Leukemia: A Clinical Phase I/II-Study

High-Dose Cytosine-Arabinoside and Mitoxantrone in Refractory Acute Myeloid Leukemia: A Clinical Phase I/II-Study

Mitoxantrone and Standard Dose Cytosine Arabinoside Therapy in Refractory or Relapsed Acute Leukemia

Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia

Contact Info

Product

Resources

About